What top creators are saying about SELLAS Life Sciences Group, Inc.(SLS)

Anticipates a significant downside crash driven by expected failure in upcoming clinical trial endpoints and poor patient outcomes.

High-conviction short opportunity driven by skepticism that its lead AML asset will fail clinical trials, with expectations the stock will head to zero.

Fundamental short opportunity based on anticipated clinical trial failure, though subject to high volatility and short squeeze risk up to $20 leading into data readout.

Considered an unviable biotech with heavily questioned drug science, viewed with high conviction as a short candidate expected to fall toward zero upon trial data release.

Maintaining a short position ahead of the 80th clinical event milestone due to physician feedback indicating a low probability (25% or lower) of clinical success.

Extremely high borrow rate and skepticism over clinical trial data suggest a strong short opportunity.

Viewed as a high-risk 'scam' with potentially manipulated trial data and historical failures in cancer vaccines.

Predicts the Regal clinical trial will fail as improved general survival rates in AML will invalidate the control group comparison.

Extremely bearish view with a strong recommendation to 'sell everything' and 'get the fuck out of it ASAP'. The speaker believes the company's drug 'does not work' and notes a 400% borrow rate, indicating high short interest.

The speaker calls the stock 'a short', but notes it is difficult to time because the data release for its 'biggest binary' event is 'very opaque'.

The speaker expressed a simple bullish sentiment, noting its recent favorable price action: 'SLS has been creeping up. I like it. Let's go.'